Skip to main content

Table 1 Characteristic of malaria patients in the study population (n = 2044) from 2011 to 2016

From: A clinical tool to predict Plasmodium vivax recurrence in Malaysia

Patient characteristic

n

Percentage (%)

Age, years, (mean, 95% CI) (range)

28.0, 27.3–28.7

2 weeks −80 years

Gender (n) (%)

 Male

1558

76.2

 Female

486

23.8

Nationality (n) (%)

 Malaysian

1310

64.1

 Non-Malaysian

734

36.0

WHO Region (n) (%)

 Africa

1

0.1

 South-East Asia

522

25.5

 Western Pacific

1367

66.8

 Eastern Mediterranean

152

7.4

 Unknown

2

0.1

Glucose-6-phosphate-dehydrogenase (G6PD) (n) (%)

 Deficient

126

6.2

 Normal

1252

61.2

 Unknown

666

32.6

Pregnancy (n) (%), total = 486

 No

448

92.2

 Yes

38

7.8

Case locality

 Urban

366

17.9

 Rural

1090

53.5

 Unknown

588

28.7

Status of case locality (n) (%)

 Free

829

40.6

 Prone

164

8

 Problematic

1033

50.5

 Unknown

18

0.9

Disease characteristic

 Length of stay (days) (mean, 95% CI) (range)

6.1, 5.9–6.3

0–45

Previous malaria infection (n) (%)

 No

1418

69.4

 Yes

454

22.2

 Unknown

172

8.4

Presence of gametocyte during admission (n) (%)

 Positive

808

39.5

 Negative

579

28.3

 Unknown

657

32.1

Gametocyte/μL on admission (mean, 95% CI) (range)

857.4, 741–972

1–19,642

Asexual/μL on admission (mean, 95% CI) (range)

6402, 5458–7346

1–732,200

Week onset (week) (mean, 95% CI) (range)

20.53, 19–21

0–52

Severity (n) (%)

 Non-severe

1961

95.9

 Severe

55

2.7

 Unknown

28

1.4

Malaria transmission type (n) (%)

 Imported

739

36.2

 Indigenous

1195

58.5

 Introduced

47

2.3

 Relapse before

63

3.1

Treatment characteristic

 Type of antimalarial drugs (n) (%)

  CQ plus PQ

1373

67.2

  ACT plus PQ

669

32.7

  No treatment

2

0.1

Status of PQ treatment (n) (%)

  Complete

2014

98.5

  Incomplete

14

0.7

  Unknown

16

0.8

  1. G6PD Glucose-6-phosphate dehydrogenase, CQ Chloroquine, PQ Primaquine, ACT Artemisinin-based combination therapies